Identification of GC-VLNs and their active component DLPC as potent inflammasome inhibitors provides new therapeutic candidates in the treatment of NLRP3 inflammasome-driven diseases.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: